SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.
Somatostatin-14 (SST) inhibits insulin and glucagon secretion by activating G protein-coupled somatostatin receptors (SSTRs), of which five isoforms exist (SSTR1-5). In mice, the effects on pancreatic β-cells are mediated by SSTR5, whereas α-cells express SSTR2. In both cell types, SSTR activation r...
Main Authors: | Kailey, B, van de Bunt, M, Cheley, S, Johnson, P, MacDonald, P, Gloyn, A, Rorsman, P, Braun, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
by: Jolanta Kunert-Radek, et al.
Published: (2010-06-01) -
Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
by: Kristof Harda, et al.
Published: (2020-12-01) -
Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
by: Wei Wu, et al.
Published: (2020-09-01) -
Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR)
by: Luz Kelly Anzola, et al.
Published: (2021-11-01) -
The somatostatin-secreting pancreatic δ-cell in health and disease
by: Rorsman, P, et al.
Published: (2018)